1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co.,Ltd.

TTSE:4569
1,131.00
JPY
+12.00
(+1.07%)
94.50BMarket Cap
Nov 09Next Earn
KYORIN Pharmaceutical Co.,Ltd.
TSE:4569
(Tokyo Stock Exchange)

Recent

price

1,131.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,392.47
1,381.52
1,428.08
1,490.98
1,515.58
1,614.28
1,570.58
1,502.32
1,731.49
1,919.9
1,796.01
1,841.72
1,976.68
2,082.94
2,264.57
2,197.77
- -
Revenue per Share
146.21
123.54
165.74
160.94
161.63
184.27
99.44
89.26
104.68
107.34
106.99
68.62
82.42
95.41
158.17
60.02
- -
Basic EPS, GAAP
70.98
91.94
69.76
216.79
7.18
51.27
187.06
89.39
-61.4
78.94
1.13
63.8
-129.09
-81.85
-48.52
41.86
- -
Free Cash Flow per Basic Share
49.94
44.93
44.79
50
61.98
52.37
58.84
58.73
77.23
75.87
75.87
65.74
52.61
52.5
52.49
57.5
- -
Dividend per Share
1,494.82
1,581.91
1,727.83
1,844.57
2,009.42
2,131.66
2,146.8
2,214.07
2,154.02
2,142.02
2,175.46
2,172.82
2,189.38
2,275.64
2,372.27
2,479.27
- -
Book Value per Share
1,483.93
1,570.59
1,715.58
1,828.54
1,993.41
2,115.36
2,130.42
2,190.35
2,094.65
2,083.86
2,109.4
2,115.43
2,095.27
2,187.08
2,289.46
2,408.16
- -
Tangible Book Value per Share
75
75
75
75
75
74
73
74
66
57
57
57
57
57
57
57
57
Basic Weighted Avg Shares
104,069
103,232
107,031
111,400
113,121
119,483
115,373
110,640
113,620
109,983
102,904
105,534
113,270
119,532
130,087
126,257
- -
Sales/Revenue/Turnover
15.8
14.01
16.77
15.81
13.03
16.43
9.03
7.97
7.9
6.82
5.62
4.75
4.52
5.22
9.66
2.83
- -
Operating Margin (%)
2,671
2,510
2,866
3,217
3,053
3,730
3,619
3,644
2,940
3,221
3,564
3,714
3,840
4,290
4,603
4,663
- -
Depreciation Expense
10,927
9,231
12,422
12,025
12,064
13,639
7,305
6,574
6,869
6,149
6,130
3,932
4,723
5,475
9,086
3,448
- -
Net Income, GAAP
36.23
39.52
33.23
34.33
31.3
27.5
24.81
27.44
26.61
25.51
26.6
24.62
31.6
24.37
28.85
22.51
- -
Effective Tax Rate (%)
10.5
8.94
11.61
10.79
10.66
11.42
6.33
5.94
6.05
5.59
5.96
3.73
4.17
4.58
6.98
2.73
- -
Profit Margin (%)
74,006
76,465
85,368
93,237
101,291
110,431
101,234
94,812
73,424
85,730
86,620
84,194
84,047
73,749
101,023
105,774
- -
Working Capital
460
361
435
501
2,504
4,469
4,108
4,323
3,010
13,052
11,445
11,177
10,843
559
20,704
20,783
- -
LT Debt
111,706
118,200
129,098
137,820
148,600
157,049
157,836
163,296
123,395
122,710
124,660
124,507
125,460
130,733
136,284
142,425
- -
Total Equity
8.9
7.1
9.28
8.35
6.81
8.85
4.73
3.82
4.13
3.78
2.88
2.57
2.37
3.13
5.58
1.65
- -
Return on Invested Capital (%)
9.63
7.69
9.84
8.87
8.25
8.64
4.48
3.97
4.38
4.23
4.22
2.72
3.26
3.7
5.82
2.2
- -
Return on Capital (%)
10.09
8.03
10.05
9.01
8.42
8.92
4.64
4.09
4.79
5
4.96
3.16
3.78
4.27
6.81
2.47
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
2,300
3,002
- -
LT Borrowings
20,135
20,444
- -
LT Finance Leases
- -
339
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
57
57
Market Capitalization
85,028
94,499
66,408

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
130,333
135,142
- -
Cash, Cash Equivalents & STI
15,131
15,081
- -
Accounts Receivable, Net
37,816
47,341
- -
Inventories
71,558
67,788
- -
Total Current Liabilities
27,756
29,368
- -
Payables & Accruals
- -
- -
- -
ST Debt
2,300
3,002
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.58%
2.72%
4.51%
Free Cash Flow
469.68%
991.77%
-186.29%
Net Income, GAAP
-5.87%
0.82%
-62.05%
Sales/Revenue/Turnover
0.68%
4.26%
-2.94%
Total Cash Common Dividend
-0.92%
-4.75%
9.55%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
130,087
2026
- -
- -
- -
- -
126,257
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
158.17
2026
- -
- -
- -
- -
60.02
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
52.49
2026
- -
- -
- -
- -
57.5
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
KYORIN Holdings, Inc. serves global healthcare needs through its diversified pharmaceutical operations, encompassing the research, development, manufacturing, and distribution of both specialized and general medicines primarily in Japan and internationally. Known now as KYORIN Pharmaceutical Co., Ltd., following a merger with its subsidiary in April 2023, the company maintains its foundational commitment to health. Its portfolio features a range of ethical drugs, including Flutiform for asthma management and Desalex, an antiallergic treatment. Offerings for overactive bladder conditions include Beova and Uritos, while Lasvic provides quinolone synthetic antibacterial action. For inflammatory bowel diseases, Pentasa is available for ulcerative colitis and Crohn's disease, and Nasonex and Mometasone KYORIN address allergic rhinitis. Additional ethical preparations consist of Kipres for bronchial asthma and allergic rhinitis, and Mucodyne, a mucoregulating agent. Beyond prescription medications, the company also supplies generic drugs through its KYORIN Rimedio subsidiary, aiming for a stable supply of high-quality, cost-effective options. Its diverse product line extends to over-the-counter pharmaceuticals, medical diagnostics such as the GeneSoC real-time PCR system, environmental hygiene products like Rubysta disinfectant cleaner and Milton disinfectant, as well as prescription medicines, quasi-drugs, and industrial chemicals. KYORIN further provides contract drug manufacturing services. The company actively engages in the discovery and assessment of potential drug compounds, alongside studying external technologies and gathering clinical trial insights, with a focus on respiratory, urology, otolaryngology, and infectious disease areas. Recent initiatives include a collaboration to advance digital therapeutics for tinnitus. Established in 1923, KYORIN Holdings, Inc. maintains its corporate headquarters in Tokyo, Japan.